A CLL RESEARCH CONSORTIUM (CRC) PHASE II STUDY OF KINETIC BIOMARKERS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究是一项纳入150例患者的前瞻性研究，旨在探讨细胞增殖和死亡的直接动力学生物标志物作为CLL疾病进展预测试验的价值，目的如下： 第一章 通过2-4年的前瞻性研究，建立体内B-CLL动力学的动力学生物标志物测量的灵敏度和特异性，作为预测150例B-CLL患者后续临床病程的测试。 （二） 将B-CLL患者的动力学生物标志物测量与其他已建立和候选预后测试进行比较。 第三章 在一个患者亚组中，比较骨髓和外周血中B-CLL细胞的动力学。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is a prospective study of 150 patients addressing the value of a direct kinetic biomarker of cell proliferation and death as a predictive test of CLL disease progression with the following objectives: 1) Establish the sensitivity and specificity of the kinetic biomarker measurement of in vivo B-CLL kinetics as a test for predicting subsequent clinical course in 150 B-CLL patients, through a 2-4 year prospective study. 2) Compare the kinetic biomarker measurement in B-CLL patients to other established and candidate prognostic tests. 3) In a subset of patients, compare the kinetics of B-CLL cells in bone marrow and peripheral blood.